Share on StockTwits

Omnicare (NYSE:OCR) has earned a consensus recommendation of “Buy” from the seven analysts that are presently covering the company, Analyst Ratings.Net reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $68.17.

A number of research firms have recently commented on OCR. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Omnicare in a research note on Thursday, July 24th. They now have a $73.00 price target on the stock, up previously from $68.00. Separately, analysts at Barclays initiated coverage on shares of Omnicare in a research note on Thursday, July 17th. They set an “equal weight” rating on the stock. Finally, analysts at Bank of America reiterated a “buy” rating on shares of Omnicare in a research note on Friday, June 20th. They now have a $73.00 price target on the stock, up previously from $69.00.

Shares of Omnicare (NYSE:OCR) traded down 0.35% on Wednesday, hitting $63.04. 78,908 shares of the company’s stock traded hands. Omnicare has a 52 week low of $52.26 and a 52 week high of $67.49. The stock’s 50-day moving average is $65. and its 200-day moving average is $61.92. The company’s market cap is $6.169 billion.

Omnicare (NYSE:OCR) last announced its earnings results on Wednesday, July 23rd. The company reported $0.91 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.90 by $0.01. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same quarter last year, the company posted $0.90 earnings per share. Omnicare’s revenue was up 7.2% compared to the same quarter last year. On average, analysts predict that Omnicare will post $3.69 earnings per share for the current fiscal year.

Omnicare, Inc (NYSE:OCR) is a healthcare services company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.